Halo Pharma Shares Expertise on Fixed-Dose Combination Products as an Effective Approach to Simplified Dosing
Halo Pharma Shares Expertise on Fixed-Dose Combination Products as an Effective Approach to Simplified Dosing Anthony Qu, PhD, Vice President Scientific Affairs, Presents at CPhI NA Whippany, NJ, April 5, 2018 – Halo Pharma Read More
Halo Pharma Partners with Pharmaceutical Companies to Formulate and Manufacture a Broad Range of Fixed-Dose Combination Drug Products
Halo-Produced FDC Drugs Already Approved and in Development Benefit Patients, Reduce Costs, and Can Extend Patent Life and Market Dominance Whippany, NJ, November 2, 2017 - Halo Pharma ("Halo") provides its pharmaceutical manufacturing partners Read More
Halo Pharma Makes Donation to the American Red Cross and Encourages Others to Help Those Affected by Hurricanes Harvey and Irma
Halo Pharma (“Halo”) has made a donation to the American Red Cross to support the humanitarian organization's ongoing efforts to provide emergency aid and disaster relief for the people affected by Hurricane Harvey and Read More
Halo Pharma Welcomes Itzhak Krinsky, Ph.D. to Its Board of Directors
Halo Pharma Welcomes Itzhak Krinsky, Ph.D. to Its Board of Directors Whippany, NJ - Halo Pharma, a rapidly growing Contract Development and Manufacturing Organization (CDMO), is pleased to announce that Dr. Itzhak Krinsky has Read More
Halo Pharma’s Pediatric Center of Excellence
Whippany, NJ, May 10, 2017 - Halo Pharma announces the formation of its Pediatric Center of Excellence in support of the development and manufacture of dosage forms tailored for pediatric indications. Halo Pharma has Read More
Halo Pharma is selected by Mezzion Pharma for Phase 3 Manufacturing of udenafil
Mezzion hired Pol Pharma and Halo Pharma to replace former contractor Dr. Reddy's which it says hid manufacturing problems that prompted the US FDA rejects its erectile dysfunction candidate, udenafil. View Full Press Release Read More